Clinical outcomes with daptomycin: a post-marketing, real-world evaluation

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Pharmacy

Background:

• The Cubicin Outcomes Registry and Experience (CORE) is a retrospective database tracking daptomycin use in the USA.
• CORE provides real-world data on daptomycin efficacy in diverse Gram-positive infections and patient populations.
• Daptomycin is a lipopeptide antibiotic used for serious Gram-positive bacterial infections.

Purpose of the Study:

• To evaluate the real-world clinical outcomes of daptomycin treatment in a broad range of Gram-positive infections.
• To assess the effectiveness of daptomycin as both first-line and salvage therapy.
• To analyze factors influencing daptomycin treatment success, including causative pathogen and vancomycin MIC.

Main Methods:

• Retrospective analysis of the CORE post-marketing database.
• Inclusion of patients with various Gram-positive infections treated with daptomycin.
• Assessment of clinical success rates and comparison of outcomes based on treatment strategy and patient characteristics.

Main Results:

• High rates of clinical success were observed for indicated infections (complicated skin and soft tissue infections, Staphylococcus aureus bacteremia, right-sided infective endocarditis) and non-indicated infections (osteomyelitis).
• Treatment outcomes were consistent across different causative pathogens and were not significantly affected by vancomycin minimum inhibitory concentration (MIC).
• Similar efficacy was noted whether daptomycin was used as initial therapy or as a salvage treatment for refractory infections.

Conclusions:

• Daptomycin exhibits high clinical effectiveness in real-world settings for various Gram-positive infections.
• Daptomycin's efficacy is robust, irrespective of the specific pathogen or prior antibiotic exposure.
• The data support daptomycin's utility as both a first-line agent and a salvage therapy option for challenging Gram-positive infections.